TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05991427

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Shingrix
Description: 2 doses of Shingrix vaccine on Day 0 and Month 4

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IH ChAdOx1-VZV
Description: 2 doses of ChAdOX1-VZV vaccine on Day 0 and Month 4

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: IH saline
Description: 2 doses of saline on Day 0 and Month 4
Study: NCT04372875

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHS-derived CDS
Description: This intervention will provide electronic clinical decision support for adolescents who screen at risk or at high risk of an STI.
Study: NCT06019910

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Snus with or without tobacco
Description: At baseline, participants have used the intervention daily for at least 30 days. They will then cease usage of the intervention abruptly. After 3 weeks, they may continue to abstain from the intervention or relapse at their own discretion.
Study: NCT05920564

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper fibers of trapezius stretching
Description: The Upper fibers of trapezius stretching intervention involves specific stretching exercises designed to target the upper fibers of the trapezius muscle. The stretching exercises will be performed under the guidance of a licensed physical therapist and will involve extending the neck while gently pulling the head downward to stretch the upper fibers of the trapezius muscle. The intervention is designed to improve neck range of motion, reduce pain intensity, and reduce disability in patients with cervical spondylosis. The duration and frequency of the stretching exercises will be standardized across participants, and adherence will be monitored throughout the study period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: The Control Group in this study will receive standard care, including heat treatment and strengthening exercises, but will not receive the specific Upper fibers of trapezius stretching intervention that is being tested in the Treatment Group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: The Control Group in this study will receive standard care, including heat treatment and strengthening exercises, but will not receive the specific Upper fibers of trapezius stretching intervention that is being tested in the Treatment Group.
Study: NCT06396663

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapid Opioid de-escalation
Description: Option 1: 10% - 50% decrease/day until opioids discontinued (≤ 10 days). For Fentanyl patches in decrements of 12 mcg/hr.~Option 2: Stop all opioid medication completely

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gradual Opioid de-escalation
Description: Option 1: 20% - 50% decrease/weekly until opioids discontinued Option 2: 10% - 20% decrease/weekly until 30 mg daily. Then reduce by 5% - 10% everyday.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuation of opioids
Description: Continue on opioids and review in 1 weeks time.
Study: NCT06509724

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Fractionated IMRT
Description: * Dose: 1.8-2.0 Gy per session, total 25-28 sessions (40-50.4Gy)~* Chemotherapy: Weekly, total 5-6 sessions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated IMRT
Description: * Dose: 2.5 Gy per session, total 16 sessions (40Gy)~* Chemotherapy: Weekly, total 3 sessions
Study: NCT05383742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin (RIF)
Description: Rifampicin 35 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH)
Description: Isoniazid 10 or15 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid (LZD)
Description: 1200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide (PZA)
Description: 25 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrazinamide (PZA)
Description: 25 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ethambutol (EMB)
Description: 20 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin
Description: 10 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: 5 mg/kg
Study: NCT06344091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Liposome Injection
Description: Bupivacaine Liposome Injection 4 mg/kg (up to a maximum of 266 mg)
Study: NCT05493410

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TREATMENT GROUP (TG)
Description: In addition to muscle strengthening and aerobic exercise, patients from the TG will undergo IMT for six weeks, performing two sets of 30 repetitions daily using the device POWERbreathe classic medic® (POWERbreathe International Ltd., Southam, United Kingdom). MIP will be measured in all patients before the intervention as described earlier, and patients will exercise at 40% MIP in the first week and 60% MIP in the subsequent five weeks. The patients will be instructed to inhale using the diaphragm muscle, trying to expand the rib cage to avoid using accessory muscles A nose clip will be used to ensure patients breathe exclusively through the training device.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CONTROL GROUP (CG)
Description: For six weeks the CG will perform muscle strengthening through a sit and stand up from a chair routine, abduction of upper and lower limbs, and rowing; three sets of 10 repetitions of each exercise will be performed. Elastic tubes will be used, with elasticity defined by color and indicating the greatest resistance the participant can endure with an effort between 4 and 8 on the OMNI-RES scale for perceived exertion.~In addition, aerobic exercise will be performed, through walking on flat terrain for five minutes in the first week, 10 minutes in the second week, and 20 minutes in the subsequent week, with intensity between 40-60% of the reserve heart rate and respecting the patients' symptoms.~Aerobic training intensity will be calculated by the modified BORG exertion scale maintaining a score between 6 and 7 - with the progression respecting the patients' symptoms - and by the reserve heart rate.
Study: NCT06553430

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobics exercises
Description: Moderate-intensity aerobic exercise for 30-60 min 3 times per week for 12 weeks
Study: NCT04930783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-301
Description: Administered as an injection given underneath the skin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-301
Description: Administered as an injection given underneath the skin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NEOVAX
Description: Personalized neoantigen vaccine administered as an injection given underneath the skin
Study: NCT06311786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-BIIB091
Description: Administered as specified in the treatment arm.
Study: NCT04926142

Intervention type: DEVICE
Intervention: Implantation of Holter device
Description: Implantation of a Holter device (Reveal Linq, Medtronic) for telemonitoring of cardiac rhythm
Study: NCT05692076

Intervention type: DEVICE
Group type: OTHER
Intervention: High Velocity Nasal Insufflation
Description: High-flow humidified oxygen with flow rates from 30 to100 L/min with high fraction of inspired oxygen( FiO2) is able to be delivered.
Study: NCT04926142

Intervention type: PROCEDURE
Intervention: Percutaneous PFO closure
Description: Patients will undergo percutaneous closure of patent foramen ovale
Study: NCT04930783

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NEOVAX
Description: Personalized neoantigen vaccine administered as an injection given underneath the skin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Administered intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered intravenously (IV)
Study: NCT05692076

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Velocity Nasal Insufflation
Description: High-flow humidified oxygen with flow rates from 30 to100 L/min with high fraction of inspired oxygen( FiO2) is able to be delivered.
Study: NCT04892121

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prevention exercises
Description: Participants will have to follow a warm-up prevention program (15 minutes) twice a week
Study: NCT05253638

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Macrophage migration inhibitory factor
Description: Assessment of disease activity: This assessment will be performed using the systemic lupus erythematosus disease activity index (SLEDAI). The SLEDAI is an index designed to assess disease activity in the preceding 10 days, with 24 weighted clinical and laboratory variables corresponding to 9 different organs/systems. The SLEDAI score ranges from 0 to 105 Renal activity will be evaluated with the renal-SLEDAI (rSLEDAI), which represents the sum of the renal items of the SLEDAI. The rSLEDAI includes the following items: proteinuria, pyuria, erythrocyturia, and urine casts; each one is scored with 0 meaning absence or 4 points meaning presence; therefore, the maximum rSLEDAI is 16
Study: NCT06203912

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow aspiration and biopsy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiography

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary study

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Universal Donor Expanded TGF-beta-imprinted NK Cells
Description: Given IV
Study: NCT05113459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy
Description: disitamab vedotin：2.5mg/kg, iv,d1,q2w,6cycle PD-1(Sintilimab ):200mg,iv,d1,q2w,6cycle Capecitabine:1000mg/m2,po,bid,d1-14,q3w,4cycle
Study: NCT05018117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine gum
Description: The effects of over-the-counter nicotine gum will be compared to a placebo gum
Study: NCT05410054

Intervention type: OTHER
Intervention: no intervention
Description: observational research

Intervention type: OTHER
Intervention: no intervention
Description: observational research
Study: NCT05018117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine gum
Description: The effects of over-the-counter nicotine gum will be compared to a placebo gum

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gum
Description: The effects of over-the-counter nicotine gum will be compared to a placebo gum

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gum
Description: The effects of over-the-counter nicotine gum will be compared to a placebo gum
Study: NCT06171061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yangxinshi tablet
Description: In addition to basic medication, the experimental group will be given Yangxinshi (three tablets each time, three times a day);The treatment period is 24 weeks.
Study: NCT05852795

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality-mediated Mindfulness-Based Interventions
Description: The Experimental will undergo 8 weekly sessions of immersive experience lasting 30 minutes. Each session is divided as follows:~* First phase: Detection of physiological parameters with Oculus equipment switched off (10 minutes).~* Second phase: Detection of physiological parameters with Oculus instrumentation turned ON during mindfulness experience (10 minutes~* Third phase: Detection of physiological parameters with Oculus equipment switched off (10 minutes).~This intervention will produce a multisensory experience merging visual and digital auditory stimuli. The audio recording also included some ambient natural sound effects, to make the practice more immersive.

Intervention type: OTHER
Group type: OTHER
Intervention: Virtual Reality-mediated Mindfulness-Based Interventions without audio guided experience
Description: The Control will undergo 8 weekly sessions of immersive experience lasting 30 minutes. Each session is divided as follows:~* First phase: Detection of physiological parameters with Oculus equipment switched off (10 minutes).~* Second phase: Detection of physiological parameters with Oculus instrumentation turned ON during mindfulness experience (10 minutes~* Third phase: Detection of physiological parameters with Oculus equipment switched off (10 minutes).~This intervention will produce a monosensorial experience with video guided stimulation of naturalistic scenarios.
Study: NCT05618535

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Doppler.
Description: Spontaneous arterial blood pressure will be simultaneously recorded using a servo-controlled plethysmograph on the left or right middle finger with an appropriate finger cuff size.~Continuous cerebral blood flow velocities of bilateral middle cerebral artery will be assessed noninvasively using transcranial Doppler.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Doppler.
Description: Spontaneous arterial blood pressure will be simultaneously recorded using a servo-controlled plethysmograph on the left or right middle finger with an appropriate finger cuff size.~Continuous cerebral blood flow velocities of bilateral middle cerebral artery will be assessed noninvasively using transcranial Doppler.
Study: NCT06610461

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HFNO-Treatment
Description: The investigated intervention is the application of HFNO throughout a high-risk upper GI-endoscopy. Concentration of oxygen is 100%. Prior to induction, flow rate is set to 20 l/min and increased to 30 l/min if tolerated by the patient. After induction of anesthesia, flow rate is increased to 60 l/min and maintained throughout the anesthesia.
Study: NCT06616207

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (Double distilled water matched in color and taste) will be applied topically by the graduate student to all tooth surfaces at the consultation appointment before the placement of fixed appliances and at 3, 6, and 9 months after appliance placement.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-iodine solution
Description: Povidone-iodine solution will be applied topically by the graduate student to all tooth surfaces at the consultation appointment before the placement of fixed appliances and at 3, 6, and 9 months after appliance placement.
Study: NCT05365659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IKS03
Description: IKS03 is a human monoclonal antibody (Ab) targeting CD19 linked to a pyrrolobenzodiazepine (PBD) pro-drug as the cytotoxic agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IKS03
Description: IKS03 is a human monoclonal antibody (Ab) targeting CD19 linked to a pyrrolobenzodiazepine (PBD) pro-drug as the cytotoxic agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IKS03
Description: IKS03 is a human monoclonal antibody (Ab) targeting CD19 linked to a pyrrolobenzodiazepine (PBD) pro-drug as the cytotoxic agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IKS03
Description: IKS03 is a human monoclonal antibody (Ab) targeting CD19 linked to a pyrrolobenzodiazepine (PBD) pro-drug as the cytotoxic agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IKS03
Description: IKS03 is a human monoclonal antibody (Ab) targeting CD19 linked to a pyrrolobenzodiazepine (PBD) pro-drug as the cytotoxic agent.
Study: NCT06617338

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CT scan unilateral knee
Description: Intervention given to the Active Comparator arm
Study: NCT06171061

Intervention type: OTHER
Group type: OTHER
Intervention: Basic medication
Description: The control group will be given basic medication only. The treatment period is 24 weeks.
Study: NCT04206761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVM149
Description: QVM149 is an investigational drug consisting of 150μg indacaterol acetate, 50μg glycopyrronium bromide and 160μg mometasone furoate. The drug is delivered as powder in hard capsules via Breezhaler, a breath-activated device which will deliver a specific dose of medication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High Dose Dual Therapy (ICS/LABA)
Description: High dose inhaled corticosteroid (ICS)/long-acting beta2-agonist (LABA) in any approved drug formulation and delivery device.
Study: NCT06107530

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: semi structured interview
Description: Women fulfilling the inclusion / exclusion criteria will be asked to participate to a semi structured interview with a psychiatrist or a psychologist
Study: NCT06617338

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT scan bilateral knee
Description: Intervention given to the Experimental Arm
Study: NCT06616168

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Microbiological identification kits (ANAEROtest, STAPHYtest, ENTEROtest, NEFERMtest)
Description: Microbiological identification kits (ANAEROtest, STAPHYtest, ENTEROtest, NEFERMtest) produced by Erba Lachema leads to bacteria detection via biochemical features

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Microbiological identification kits (ANAEROtest, STAPHYtest, ENTEROtest, NEFERMtest)
Description: Microbiological identification kits (ANAEROtest, STAPHYtest, ENTEROtest, NEFERMtest) produced by Erba Lachema leads to bacteria detection via biochemical features

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Microbiological identification kits (ANAEROtest, STAPHYtest, ENTEROtest, NEFERMtest)
Description: Microbiological identification kits (ANAEROtest, STAPHYtest, ENTEROtest, NEFERMtest) produced by Erba Lachema leads to bacteria detection via biochemical features

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy after the results of antibiotic sensitivity test (Mostly Oxacillin, Benzylpenicillin, Ceftriaxone, Doxycycline, Clindamycin)
Description: Antibiotic therapy after the results of antibiotic sensitivity test. Aminoglycosides, Carbapenems, Cephalosporins, Fluoroquinolones, Oxazolidinones are used. Mostly Oxacillin, Benzylpenicillin, Ceftriaxone, Doxycycline, Clindamycin are used for the therapy.
Study: NCT05753176

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online 1-Day Cognitive Behavioural Therapy-Based Workshop
Description: The Online Workshop is a day-long intervention delivered by two trained facilitators (i.e., psychotherapists, social workers, nurses, and/or a psychiatrist) consisting of 6 hours of instruction delivered in 4 modules. The 1st contains information on PPD etiology with a focus on modifiable cognitive risk factors (e.g., negative thoughts, maladaptive core beliefs). The 2nd module focuses on cognitive skills including cognitive restructuring. The 3rd builds behavioural skills such as problem solving, behavioural activation, assertiveness, sleep strategies, and using supports. The final module provides an opportunity for goal setting/action planning. Teaching methods include didactic sections, group exercises, and role-plays. Regular breaks are incorporated. Each participant is given a professionally designed manual to facilitate learning. Participants are also given a list of region-specific PPD resources and a copy of the Canadian Practice Guidelines for the treatment of PPD.
Study: NCT04544306

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Partial oral antimicrobial therapy
Description: Switch intravenous antimicrobial therapy to oral after an initial period of 10 days to oral antimicrobial therapy. Antimicrobial choices will be guided by antimicrobial susceptibilities.
Study: NCT06616168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy after the results of antibiotic sensitivity test (Mostly Oxacillin, Benzylpenicillin, Ceftriaxone, Doxycycline, Clindamycin)
Description: Antibiotic therapy after the results of antibiotic sensitivity test. Aminoglycosides, Carbapenems, Cephalosporins, Fluoroquinolones, Oxazolidinones are used. Mostly Oxacillin, Benzylpenicillin, Ceftriaxone, Doxycycline, Clindamycin are used for the therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy after the results of antibiotic sensitivity test (Mostly Oxacillin, Benzylpenicillin, Ceftriaxone, Doxycycline, Clindamycin)
Description: Antibiotic therapy after the results of antibiotic sensitivity test. Aminoglycosides, Carbapenems, Cephalosporins, Fluoroquinolones, Oxazolidinones are used. Mostly Oxacillin, Benzylpenicillin, Ceftriaxone, Doxycycline, Clindamycin are used for the therapy.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Suppositoria for vaginal microflora recovery (Giynoflor)
Description: Prescription of suppositoria for vaginal microflora recovery after antibiotic therapy. Probiotic grug includes Lactobacilli acidophillis as the main compound.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Suppositoria for vaginal microflora recovery (Giynoflor)
Description: Prescription of suppositoria for vaginal microflora recovery after antibiotic therapy. Probiotic grug includes Lactobacilli acidophillis as the main compound.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Suppositoria for vaginal microflora recovery (Giynoflor)
Description: Prescription of suppositoria for vaginal microflora recovery after antibiotic therapy. Probiotic grug includes Lactobacilli acidophillis as the main compound.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antifungal therapy (Mostly Fluconazole, Nystatin, Amphotericin B)
Description: Prescription of antifungal drugs. Triazoles (Fluconazole, Itraconazole, Voriconazole), Imidazoles (Ketoconazole), Nystatin and Amphotericin B are used the most

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antifungal therapy (Mostly Fluconazole, Nystatin, Amphotericin B)
Description: Prescription of antifungal drugs. Triazoles (Fluconazole, Itraconazole, Voriconazole), Imidazoles (Ketoconazole), Nystatin and Amphotericin B are used the most